Curida specializes in the development and manufacturing of pharmaceuticals, focusing on small molecule formulations and liquid pharmaceuticals. Their expertise includes the use of sterile blow-fill-seal (BFS) technology and nasal spray production, ensuring safe and effective delivery of life-improving products. The company offers a comprehensive range of services, from product formulation and analytical method validation to stability studies and regulatory processes. Curida also emphasizes tech transfer, facilitating the transition of products from small-scale to large-scale manufacturing while adhering to industry best practices.

In addition to small molecules, Curida has expanded its capabilities through the acquisition of Diatec, which specializes in the production and conjugation of monoclonal antibodies. This enhancement allows Curida to offer biologics as part of its portfolio. The company serves Norwegian pharmacies with raw materials and liquid products, including special pharmaceuticals and cosmetics. Curida's commitment to quality and responsibility underpins its operations, ensuring that they meet the needs of their clients while maintaining high standards in pharmaceutical development and manufacturing.

Norway

Curida is a Contract Development and Manufacturing Organization for Pharmaceuticals, based in Norway.  We are building on more than 40 years of experience and offer premium quality manufacturing to international pharma companies. 

Curida has core competency on sterile and aseptic manufacturing of liquid pharmaceuticals. Our core technologies are blow-fill-seal (BFS) and nasal spray.

We work with companies ranging from small biotech to Big Pharma. We have a lean and flexible organization that will, enabling a strong partnership with our customers.

Curida

Company Details